Alnylam announces a three-year collaboration with Inceptive Nucleics aimed at using artificial intelligence foundation models to support research and development for RNA interference (RNAi) therapeutics. According to STAT News, the agreement is worth up to $2 billion total, with an initial $30 million provided upfront in cash and equity. The partnership is structured as a finite-duration program, described as spanning three years, and focuses on applying AI foundation models to areas relevant to RNAi drug development. The Seeking Alpha report similarly characterizes the collaboration as centered on using AI to aid RNAi therapy development, though it provides fewer deal-specific details in the excerpt provided. Together, the accounts describe a major strategic effort by Alnylam to work with a startup specializing in AI models, with financial terms that include both early payment and potential additional payments tied to the collaboration over time. No additional information is provided in the provided excerpts about specific model capabilities, target therapeutic programs, or milestones beyond the reported deal size and structure.